IDYAIDEAYA Biosciences, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $37.73 · now $37.73 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, IDYA has typically landed between $30.44 and $47.18 — a range of −19.3% to +25.1% from the issuance price $37.73.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,818 overlapping 1 month windows · 2019-05-232026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($37.73) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where IDYA has typically landed a month from the 2026-09-16 close of $37.73 — the range is history, not a prediction.

$30.44worst · -19.3%$47.18best · +25.1%
  • now $37.73 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $37.79 (+0.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $34.13$41.46
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $30.44$47.18
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,818 windows spanning 2019-05-23 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-02-14−55.4%−55.4%+6.6%
2020-02-18−53.2%−54.8%+7.9%
2020-02-13−52.6%−52.6%+3.0%
3 best
2020-05-18+152.7%−4.9%+152.7%
2020-05-22+103.6%+0.0%+165.7%
2020-05-26+101.5%+0.0%+158.3%

1,818 overlapping windows · 2019-05-232026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
43%
+1.9%
n=7
Feb
57%
−5.6%
n=7
Mar
29%
−10.6%
n=7
Apr
43%
+6.2%
n=7
May
57%
+15.1%
n=7
Jun
75%
+11.0%
n=8
Jul
50%
+1.7%
n=8
Aug
38%
−1.2%
n=8
Sep
63%
+9.2%
n=8
Oct
43%
−5.2%
n=7
Nov
86%
+11.8%
n=7
Dec
57%
+1.7%
n=7

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$42$232026-07-07: 1 insider sale, $382K — Ruiz Briseno Andres2026-03-02: 1 insider purchase, $1.6M — Stein Jeffrey2026-03: 1 open-market purchase, $1.6M2026-07: 1 open-market sale, $382K↑ buys↓ salesofficer Ruiz Briseno Andres — Sale on 2026-07-07, filed 2 days after the tradedirector Stein Jeffrey — Purchase on 2026-03-02, filed same day
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-07Ruiz Briseno AndresofficerSale9,550 @ $40.01$382K−26.5% of holding−14.0%not yet — horizon still open26,466Form 4 · filed 2 days after the trade
2026-03-02Stein JeffreydirectorPurchase50,000 @ $32.96$1.6M+1168.0% of holding+5.8%+9.0%54,281Form 4 · filed same day

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

33 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-07Ruiz Briseno AndresofficerOption exercise9,55036,016Form 4
2026-07-07Ruiz Briseno AndresofficerOption exercise9,55019,200Form 4
2026-06-16ROSEN TERRY JdirectorAward / grant20,00020,000Form 4
2026-06-16Stein JeffreydirectorAward / grant20,00020,000Form 4
2026-06-16YARNO WENDY LdirectorAward / grant20,00020,000Form 4
2026-06-16Morrison Scott WdirectorAward / grant20,00020,000Form 4
2026-06-16Hampton Malcolm GarretdirectorAward / grant20,00020,000Form 4
2026-06-16MACKEY CATHERINE JdirectorAward / grant20,00020,000Form 4
2026-01-30Snyder Douglas B.officerAward / grant130,000130,000Form 4
2026-01-30Beaupre DarrinofficerAward / grant175,000175,000Form 4
2026-01-30Bleharski JoshuadirectorAward / grant170,000170,000Form 4
2026-01-30Ruiz Briseno AndresofficerAward / grant80,00080,000Form 4
2026-01-30Hata Yujiro SdirectorAward / grant600,000600,000Form 4
2026-01-30WHITE MICHAEL ANTHONYofficerAward / grant190,000190,000Form 4
2026-01-30DORMAN STUARTofficerAward / grant155,000155,000Form 4
2025-11-28Ruiz Briseno AndresofficerAward / grant1,25326,466Form 4
2025-11-28Snyder Douglas B.officerAward / grant1,0412,080Form 4
2025-06-24Stein JeffreydirectorAward / grant20,00020,000Form 4
2025-06-24YARNO WENDY LdirectorAward / grant20,00020,000Form 4
2025-06-24Morrison Scott WdirectorAward / grant20,00020,000Form 4
2025-06-24Hampton Malcolm GarretdirectorAward / grant20,00020,000Form 4
2025-06-24ROSEN TERRY JdirectorAward / grant20,00020,000Form 4
2025-06-24MACKEY CATHERINE JdirectorAward / grant20,00020,000Form 4
2025-05-30Snyder Douglas B.officerAward / grant1,0391,039Form 4
2025-02-27Hata Yujiro SdirectorAward / grant600,000600,000Form 4
2025-02-27Snyder Douglas B.officerAward / grant33,00033,000Form 4
2025-02-27WHITE MICHAEL ANTHONYofficerAward / grant185,000185,000Form 4
2025-02-27Beaupre DarrinofficerAward / grant185,000185,000Form 4
2025-02-27Ruiz Briseno AndresofficerAward / grant75,00075,000Form 4
2025-02-27DORMAN STUARTofficerAward / grant15,00015,000Form 4
2025-02-18Hata Yujiro SdirectorOption exercise12,808690,695Form 4
2025-02-18Hata Yujiro SdirectorOption exercise12,808182,192Form 4
2024-11-29Ruiz Briseno AndresofficerAward / grant68225,213Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.